Brind.
  1. On July 23, 2025, financial reports showed that revenues for Italy, Southern Europe, and the US surpassed expectations, while Northern Europe revenues declined.

Market growth is being driven by FDA approvals and successful product launches from companies like AbbVie, Pfizer, and Regeneron in the US and Italy.

1 report, 1 independent Updated Jul 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Market growth is being driven by FDA approvals and successful product launches from companies like AbbVie, Pfizer, and Regeneron in the US and Italy.

Who's involved

What this event is mainly about
FDAPfizer

Keep exploring

Part of

On July 23, 2025, financial reports showed that revenues for Italy, Southern Europe, and the US surpassed expectations, while Northern Europe revenues declined. All 2 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAtopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to